ZYBERNO
Stock Report
Updated Sep 2, 2026

EVOLUS, INC. (EOLS)

Healthcare • NASDAQ

$8.88

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
16.0/100
POOR BUSINESS
EVOLUS, INC. (EOLS) scores 16/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-13.9%)
Return on Capital (Capital Efficiency):CRITICAL (-27.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

EVOLUS, INC. (EOLS) stock report — Zyberno Score 16/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, EOLS generated -$40.12M in Owner Earnings. Capital was deployed as follows: $3.54M invested in capital expenditures. Reinvestment rate: 12.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:8.88
Market Cap:$585.45M

Valuation Multiples (2)

P/S Ratio:1.85x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$734.75M

Price Action & Momentum (3)

Momentum Percentile:19 / 100
% of 52-Week High:97.4%
B. Profitability Assessment

Return Metrics (4)

ROA:-30.8%
Reinvestment Rate:12.3%
Fundamental Growth Rate (g):-3.4%

Margin Analysis (3)

Operating Margin Ttm:-13.9%
Net Margin Ttm:-22.2%
Ebitda Margin:-9.7%

TTM Performance (3)

Gross Margin Ttm:66.7%
Operating Margin Ttm:-13.9%
Net Margin Ttm:-22.2%

Yield Metrics (2)

Earnings Yield:-$12.16
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:53.6%
Latest Earnings Filed:2026-08-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):23.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.70x
Quick Ratio:1.28x
Cash Ratio:0.46x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-2.01x
Times Interest Earned:-2.01

Capital Structure (4)

Working Capital:68,813,000.00
Cash And Cash Equivalents:45,170,000.00
Long Term Debt:$156.74M
Net Debt:$149.30M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $316.49M
Linear Growth: 23.2%
📊 Click to view full EOLS Revenue analysis & methodology →
Cost Of Revenue Ttm:$105.28M

Profitability Breakdown (2)

Gross profit TTM: $211.21M
Linear Growth: 46.0%
📊 Click to view full EOLS Gross Profit analysis & methodology →
-$44.05M

Bottom Line Performance (3)

-$70.37M
Income Before Tax:-$69.59M
Ebitda Ttm:-30,717,000.00

Operating Expenses (5)

Operating Expenses:229,880,000.00
R And D Expense:9,659,000.00
Sga Expense:216,504,000.00
Income Tax Expense:$654.00K
Interest Expense:16,219,000.00

Expense Ratios (3)

R And D To Revenue Percentage:11.5%
Sga To Revenue Percentage:257.5%
Ebitda Margin:-9.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$248.02M
Current Assets:$167.54M
Ppe Net:5,046,000.00
Goodwill:21,208,000.00
Intangible Assets:$45.69M

Liability Structure (4)

Total Liabilities:278,927,000.00
Current Liabilities:98,731,000.00
Long Term Debt:$156.74M
Short Term Debt:$37.72M

Equity & Capital (3)

Equity:-$30.90M
Retained Earnings:-$679.77M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:62,383,000.00
Inventory:40,896,000.00
Accounts Payable:44,480,000.00

Special Items (2)

Contract Liabilities:11,586,000.00
Stock Based Compensation:5,622,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$36.59M-$40.12M

Investment Activities (2)

Investing Cash Flow:-$1.69M
Capital Expenditures Ttm:3,537,000.00

Financing Activities (3)

Financing Cash Flow:$7.62M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$10.00M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:13,336,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.08
-$1.08
Earnings Per Share Ttm:-$1.07

Revenue & Cash Per Share (2)

Sales Per Share Ttm:4.80
Operating Cash Flow Per Share:-$0.64

Book Value & Capital (2)

Book Value Per Share:-$0.47
Cash Per Share:0.69

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.39x
Working Capital Turnover Ttm:4.60x

Receivables Management (2)

Receivables Turnover Ttm:5.07x
Days Sales Outstanding Ttm:71.95

Inventory Management (2)

Inventory Turnover Ttm:2.57x
Days Inventory Outstanding Ttm:141.79

Payables & Cash Cycle (2)

Days Payable Outstanding:154.21
Cash Conversion Cycle:59.52
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$40.12M

Damodaran Growth Analysis (2)

Reinvestment Rate:12.3%
Fundamental Growth Rate (g):-3.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):23.2%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):46.0%
Book Value Growth Rate (Linear):-49.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:EOLS
Company Name:EVOLUS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:65.93M
Shares Outstanding Basic:65.93M
Shares Outstanding Diluted:65.93M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-02 04:30:30 UTC
Data Timestamp:2026-09-02T04:30:30.115517
Scroll to Top